Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 2;27(9):e755-e758.
doi: 10.1093/oncolo/oyac121.

Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment

Kimberly Loo  1   2 , Hannah L Kalvin  3 , Katherine S Panageas  3 , Vivian Park  4 , Michael A Postow  1   5
Affiliations

Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment

Kimberly Loo et al. Oncologist. .

Abstract

Background: Little is known about patient outcomes with advanced melanoma following inpatient initiation or continuation of immune checkpoint blockade (ICB).

Methods and results: We conducted a single institution retrospective case series of advanced melanoma patients who initiated ICB as an inpatient (initial inpatient cohort, n = 9), or continued ICB as an inpatient after previously starting as an outpatient (outpatient then inpatient cohort, n = 5). One patient had a partial response to ICB initiated as an inpatient, but ultimately died of melanoma after 13.5 months. Median overall survival for initial inpatient cohort was 1.0 month (95% CI: 0.2-11.2), and 1.4 months (95% CI: 0.4-58.0) for the outpatient then inpatient cohort. Three patients were alive >6 months after inpatient ICB administration.

Conclusion: Despite overall poor outcomes, some patients may benefit from inpatient ICB. This study provides additional information for clinicians to appropriately counsel patients on expectations following inpatient ICB.

Keywords: immunotherapy; inpatient treatment; melanoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival of initial inpatient and outpatient then inpatient cohorts. (A) Overall survival of initial inpatient cohort. Median overall survival of initial inpatient cohort was 1.0 month. Tick marks indicate censored patients. Shaded areas represent 95% CI. (B) Overall survival of outpatient then inpatient cohort. Median overall survival of this cohort was 1.4 months. Tick marks indicate censored patients. Shaded areas represent 95% CI.
See this image and copyright information in PMC

References

    1. Durbin SM, Zubiri L, Niemierko A, et al. . Clinical outcomes of patients with metastatic cancer receiving immune checkpoint inhibitors in the inpatient setting. The Oncologist 2021;26(1):49-55. 10.1002/onco.13561. - DOI - PMC - PubMed
    1. Wong A, Williams M, Milne D, et al. . Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma. Asia Pac J Clin Oncol. 2017;13(6):385-390. 10.1111/ajco.12702. 10.1111/ajco.12702. - DOI - DOI - PubMed
    1. Glisch C, Saeidzadeh S, Snyders T, et al. . Immune checkpoint inhibitor use near the end of life: a single-center retrospective study. J Palliat Med. 2020;23(7):977-979. 10.1089/jpm.2019.0383. - DOI - PubMed
    1. van Boemmel-Wegmann S, Brown JD, Diaby V, et al. . Health care utilization and costs associated with systemic first-line metastatic melanoma therapies in the United States. JCO Oncol Pract. 2022;18(1):e163-e174. 10.1200/OP.21.00140. - DOI - PubMed

Publication types

Substances